Last reviewed · How we verify
Mescaline sodium enteric-coated tablets
Mescaline is a naturally occurring psychedelic alkaloid that acts as a non-selective serotonin receptor agonist, primarily at 5-HT2A receptors.
Mescaline is a naturally occurring psychedelic alkaloid that acts as a non-selective serotonin receptor agonist, primarily at 5-HT2A receptors. Used for Research use; no established approved clinical indications.
At a glance
| Generic name | Mescaline sodium enteric-coated tablets |
|---|---|
| Sponsor | Xiangya Hospital of Central South University |
| Drug class | Serotonin receptor agonist; psychedelic |
| Target | 5-HT2A receptor (primary); non-selective serotonin receptors |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology (research/investigational) |
| Phase | FDA-approved |
Mechanism of action
Mescaline binds to and activates serotonin receptors, particularly the 5-HT2A subtype, which modulates perception, mood, and cognition. The enteric coating allows delayed release in the small intestine to improve tolerability and absorption. This mechanism underlies its psychoactive and potential therapeutic effects on mood and perception-related disorders.
Approved indications
- Depression or mood disorders (investigational/research use)
- Potential use in psychiatric conditions (specific approved indications unclear)
Common side effects
- Hallucinations or altered perception
- Nausea or gastrointestinal distress
- Anxiety or psychological distress
- Elevated blood pressure or heart rate
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: